Serological assays are used to diagnose and characterize host immune responses against microbial pathogens. Microarray technologies facilitate highthroughput immunoassays of antibody detection against multiple pathogens simultaneously. To improve survey of influenza A virus (IAV), influenza B virus (IBV), respiratory syncytial virus (RSV), and adenovirus (AdV) antibody levels, we developed a microarray consisting of IAV H1N1, IAV H1N1pdm09 (vaccine), IAV H3N2, IBV Victoria, IBV Yamagata, RSV, AdV type 5 hexon protein, and control antigens printed on the bottom of a microtiter plate well. Bound IgG antibodies were detected with antihuman IgG-coated photon-upconverting nanoparticles and measured with a photoluminescence imager. The performance of the microarray immunoassay (MAIA) was evaluated with serum samples (n ϭ 576) collected from children (n ϭ 288) at 1 and 2 years of age and tested by standard enzyme immunoassays (EIAs) for antibodies to IAV vaccine and RSV. EIAs and MAIA showed substantial to almost perfect agreement (Cohen's , 0.62 to 0.83). Applying MAIA, we found seroprevalences of 55% for IAV H1N1, 54% for IAV vaccine, 30% for IAV H3N2, 24% for IBV Victoria, 25% for IBV Yamagata, 38% for RSV, and 26% for AdV in 1-year-old children (n ϭ 768). By the age of 2 years, IgG seropositivity rates (n ϭ 714) increased to 74% for IAV H1N1, 71% for IAV vaccine, 49% for IAV H3N2, 47% for IBV Yamagata, 49% for IBV Victoria, 68% for RSV, and 58% for AdV. By analyzing increases in antibody levels not biased by vaccinations, we found a reinfection rate of 40% for RSV and 31% for AdV in children between 1 and 2 years of age. IMPORTANCE The multiplex immunoassay was successfully used to simultaneously detect antibodies against seven different viruses. The developed serological microarray is a new promising tool for diagnostic, epidemiological, and seroprevalence analyses of virus infections.
Respiratory syncytial virus (RSV) and influenza viruses (IAVs) are among the most common causes of respiratory infections in infants and young children, and these viruses continue to infect humans throughout their entire lives, with exceptionally high rates of reinfection. Efficacy of influenza vaccines is continuously monitored for composition adjustments, and many candidate RSV vaccines are under investigation. Human adenoviruses (AdVs) cause respiratory as well as gastrointestinal tract infections, with the highest prevalence in children under 5 years of age (7) . The global spread of the most recent pandemic IAV, the current threat of avian influenza, and the continued emergence of novel human viral respiratory pathogens underline the importance of worldwide virus surveillance systems (8) . While multiplex PCR assays provide a rapid and specific diagnosis in acute respiratory infections, detection of serum antibodies allows estimating the prevalence of an infection in a population or determination of immune status and antibody responses in vaccine studies. Recently, researchers have started to develop protein microarrays for influenza virus serology (9) (10) (11) (12) (13) (14) .
For the multiplexed immunoassays, fluorescent dyes are frequently used for detection. NaYF4:Yb 3ϩ , Er 3ϩ photon upconverting nanoparticles (UCNPs) are an exceptional alternative among luminescent labels. UCNPs convert lower-energy near-infrared (980 nm) excitation into higher-energy visible light (550 nm) emission (15) . UCNPs are exceptionally photostable, and their anti-Stokes luminescence can be measured free of autofluorescence, which enables very high sensitivity of signal detection. These novel labels have been shown to be suitable for both qualitative and quantitative microarraybased multianalyte assays (16, 17) .
In the present study, a multiplex microarray immunoassay (MAIA) was developed for simultaneous detection of serum IgG antibodies against RSV, adenovirus, different influenza virus subtypes or vaccine, and several control antigens. Biotinylated antigens were printed in a 4 ϫ 5 format on the bottom of streptavidin-coated 96-well microtiter plate wells. UCNPs coated with anti-human IgG (anti-hIgG) were used to detect serum IgG antibodies bound to the array spots. The differentiation between and strength of antibody responses against different antigens were achieved based on the position and the intensity of the signal originating from bound UCNPs. The performance of MAIA was validated with a collection of sera previously characterized with in-house enzyme immunoassays (EIAs). We then used MAIA to assess virus-specific immunity in response to natural infection and vaccination in a cohort of young children. MAIA. The area under the receiver operating characteristic (ROC) curve analysis values, 96.5 for RSV and 96.2 for IAV vaccine, indicated good performance of the microarray. Cutoff values of 12 units for anti-RSV and 8 units for anti-IAV vaccine antibodies were determined as the optimal ratios of sensitivity and specificity of the MAIA. We calculated that these cutoff values corresponded to the mean value of negative controls plus 6 standard deviations (SD). The cutoff values for IAV H1N1, IAV H3N2, IBV Yamagata, IBV Victoria, and AdV5 hexon were calculated as the means of negative controls plus 6 SD units, and they were 7, 39, 9, 12, and 5 units, respectively.
EIA and MAIA results had a high degree of correlation with each other in both negative and positive serum samples. We observed somewhat higher anti-RSV IgG unit values detected by MAIA than by EIA ( Fig. 2A and B) , whereas in the anti-IAV H1N1pdm09 vaccine antigen assay, IgG unit values were higher in the EIA ( Fig. 2C and D) . For a more corresponds to signal counts of 7,000 to 35,000, yellow to 35,000 to 45,000, and red to 45,000 to 65,000. (E) Average signal counts from no-sample well, negative control, positive control, and a serum sample positive for IgG antibodies against RSV and AdV. Average signal counts were calculated as a mean signal from 2 duplicate spots and 2 duplicate wells (from 4 spots altogether). The error bars indicate the SD of the upconversion luminescence signals. robust measurement of agreement between the assays, Cohen's kappa coefficient statistic was used. Comparing the numbers of positive and negative results ( Table 1) , we found an almost perfect overall agreement between EIA and MAIA for RSV antibodies at 1 and 2 years and for IAV vaccine antibodies at 1 year (Cohen's , 0.829, 0.815, and 0.822, respectively) and substantial agreement for IAV vaccine at 2 years (Cohen's , 0.644). IgG antibodies against RSV were detected in 37% (n ϭ 106) and 38% (n ϭ 109) of 1-year-old children by EIA and MAIA, respectively ( Fig. 3A ). By the age of 2 years, 68% (n ϭ 196) and 69% (n ϭ 199) of children had turned RSV seropositive as detected by EIA and MAIA, respectively. Anti-IAV H1N1pdm09 vaccine antigen IgG were detected in 58% (n ϭ 167) of 1-year-old children by EIA and in 57% (n ϭ 164) of 1-year-old children by MAIA ( Fig. 3B ). By the age of 2 years, these seropositivity rates increased to 83% (n ϭ 240) and 72% (n ϭ 209), respectively.
IgG antibody levels and seroprevalences. Figure 4 shows the distribution of IgG unit values, measured for the seven different virus antigens on the microarray, in all serum samples collected from 1-year-old (n ϭ 768) and 2-year-old (n ϭ 714) children. Calculated cutoffs clearly discriminate seropositive from seronegative samples. Between the time points, an increase of mean IgG levels was observed against all virus antigens, except the IAV vaccine. The rise in mean IgG levels was likely due to both reinfections and a stronger response to primary infection after the first year of life. The seroprevalence of antibodies increased against all viruses between 1 and 2 years. At 2 years of age, it had increased 1.79-fold for RSV, 2.23-fold for AdV, 1.31-fold for IAV vaccine, 1.35-fold for IAV H1N1, 1.63-fold for IAV H3N2, 2.04-fold for IBV Victoria, and 1.88-fold for IBV Yamagata (Fig. 5 ). High IgG antibody levels develop after reinfection. To further estimate seropositivity rates, antibody levels, and possible reinfection rates, serum samples collected at 1 and 2 years of age from 450 individuals were analyzed ( Fig. 6 ). Children who were seropositive for RSV, AdV, or IBV Victoria by the age of 1 year showed increased mean antibody levels at the age of 2 years, suggesting a high rate of reinfection. They were divided into 2 groups based on the change in the corresponding IgG level. An increase of Ͼ25 MAIA units was considered an indication of reinfection. Of the 170 children who had acquired RSV infection by the age of 1 year, 68 (40%) were likely to have had a reinfection by the age of 2 years (Fig. 7A) , with an increase of the mean anti-RSV IgG antibody levels from 58 to 129 MAIA units. The antibody levels of the group of 102 children without serological evidence of a reinfection (Fig. 7B ) decreased slightly, from 72 to 60 MAIA units (P ϭ 0.030). Of the 118 children who had acquired AdV infection by the age of 1 year, 37 (31%) likely had a reinfection by the age of 2 years (Fig. 7C) , with an increase of mean antibody levels from 37 to 95 MAIA units. The remaining 81 anti-AdV antibody positive individuals showed no change in the mean IgG levels (76 MAIA units versus 70 [P ϭ 0.262] [ Fig. 7D] ). Of the 108 children who had acquired IBV infection by the age of 1 year as analyzed by Victoria strain-specific reactivity, 48 (44%) were reinfected by the age of 2 years, with an increase of antibody levels from 31 to 84 MAIA units (Fig. 7E) . The other group of 60 children showed some decrease in corresponding antibodies, from 46 to 30 MAIA units (P ϭ 0.007) (Fig. 7F) . The responses to Yamagata antigen were weaker, with an increase from 23 to 52 MAIA units in the former group of 48 children, including only 17 individuals with a qualified increase of Ͼ25 MAIA units. Interestingly, the groups of children without evidence of reinfection showed 1.24-, 2.05-, and 1.48-fold-higher mean antibody levels after primary infection than the groups showing serological evidence of reinfection with RSV, AdV, and IBV Victoria, respectively. It is likely that higher antibody levels at least partly protected these children from reinfections.
RSV IgG seropositivity and reinfection rates by RSV-specific RT-PCR. From the studied group analyzed by both EIA and MAIA (n ϭ 288), 183 children were followed more intensively for respiratory tract infections. Nasal swab specimens were taken during symptoms of infection and analyzed by reverse transcription-PCR (RT-PCR) for the presence of RSV RNA. Among the 183 children, 63 had at least one RT-PCRconfirmed RSV infection. A relationship between PCR-confirmed RSV infection and RSV IgG antibody levels detected by EIA has been published previously (18) . Among the RSV RT-PCR-positive individuals by the age of 13 months, 5% (2/40) were IgG seronegative as detected by MAIA. By 2 years of age, only 1 child out of 63 (1.6%) RSV RT-PCRpositive individuals remained RSV seronegative by MAIA ( Table 2) .
DISCUSSION
In the present study, a multiplex serological MAIA was developed for simultaneous detection of serum IgG antibodies against IAV H1N1 vaccine antigen (pandemic A/California/7/2009 virus), IAV H1N1, IAV H3N2, IBV Yamagata, IBV Victoria, RSV, and AdV5 hexon protein. To validate the developed assay, serum specimens collected at 1 and 2 years of age from 288 individuals were tested by MAIA and by reference in-house IgG antibody EIAs against RSV and IAV H1N1 vaccine antigen. The detection of RSV-and IAV-specific antibodies by the multiplex MAIA was in very good agreement with results obtained by EIA reference methods. The data indicate that the developed serological microarray proved to be a reliable tool for analyzing virus-specific humoral immunity in response to natural infection and vaccination in young children.
During our study, and as a previously described pattern, a major RSV epidemic peak was observed in Finland every other winter (2010 and 2012), with minor epidemic peaks occurring between the major ones (2009 and 2011) (7) . Thus, most of our samples covered at least one RSV epidemic season. Based on anti-RSV IgG antibody seroprevalence analysis, at least 38% of young children were infected with RSV during their first year of life and 68% by the age of 2 years. Interestingly, the seroprevalence data corresponded extremely well with our previous findings from a smaller cohort analyzed by EIA (18) . Reinfection led to clearly increased serum anti-RSV IgG antibody levels. It was also of interest that the children, who had relatively high anti-RSV antibody levels at 1 year of age, did not show any further increase in antibody levels and thus were likely protected against a reinfection between 1 and 2 years of age. During the study period, various AdV types were circulating endemically, but AdV-B3 caused an outbreak in the second half of 2010 (19) . Hexon protein is known to be highly cross-reactive between AdV serotypes. In our seroprevalence analysis, at least 26% of young children were infected with AdV during their first year of life and 58% by the age of 2 years. About 31% of children who had undergone an AdV infection during their first year of life were reinfected by the age of 2 years. Reinfection led to the development of relatively high anti-AdV antibody levels. Those children who had no serological evidence of reinfection had high anti-hexon antibody levels already at the age of 1 year.
The pandemic IAV H1N1pdm09 was the prevalent IAV in Finland during the collection of 1-year samples (2009 to 2011), cocirculating with IBV in the 2010 -2011 epidemic season. The 2011-2012 season was predominated by IAV H3N2. In Finland, the pandemic vaccination coverage was ca. 80% in children aged 6 to 23 months (20) . In our study, 54% of children were seropositive against IAV H1N1 vaccine antigen by the age of 1 year and 71% by the age of 2 years. Similar seropositivity rates were detected with partially purified whole H1N1 IAV (55% and 74%, respectively). The H1N1 vaccine antigen and the epidemic IAV strain used in the analysis are genetically very close to one another, which explains the similar seropositivity rates. In contrast to all other antigens, the levels of IgG antibodies against the two IAV antigens were similar or slightly decreased by the age of 2 years, suggesting that anti-H1N1 antibodies (at the age of 1 year) protected the children against IAV infection or reinfection. Increased seropositivity by the second year was likely due to better vaccination coverage by the age of 2 years. Our data suggest that the high seropositivity rate of H1N1 IAV-specific antibodies was due to an effective vaccination campaign, and thus, we could not analyze the rate of natural IAV infection in our cohort (21) .
We also included influenza A H3N2 virus into our analyses even though the virus became epidemic only during the winter of 2011-2012 among the studied epidemic The boxes indicate the interquartile range (25 to 75%), the whiskers 1st and 99th percentiles, the horizontal lines inside the boxes the median, the squares inside boxes the mean, and the triangles the minimum and the maximum.
seasons. In our study, 30% of children were seropositive against IAV H3N2 by the age of 1 year and 49% by the age of 2 years. This was likely due to cross-reactivity of conserved internal proteins and vaccinations with the seasonal trivalent influenza vaccine recommended for all 6-to 35-month-old children during the study years. The seasonal vaccination coverage was variable; in the study population, it ranged from 22 to 47%. However, IAV H3N2 antigen gave relatively weak reactivity in the array-in-well assay, thus limiting the reliability of the cutoff value discriminating seropositive and seronegative serum specimens.
There are two evolutionary lineages of human IBVs, Victoria and Yamagata. For the study period, the IBV included in the seasonal vaccine was from the Victoria lineage, matching the strains predominating during that time (22) . In our study, 24% and 25% children were seropositive against IBV Victoria and Yamagata antigens by the age of 1 year and the seropositivity rose to 49% and 47% by the age of 2 years, respectively. Out of those children who had a primary response to IBV Victoria by the age of 1 year, 44% showed a significant increase in antibody levels, indicating a likely IBV reinfection or reimmunization. Most of our 2-year samples were collected in 2011, suggesting that there were a relatively high number of IBV Victoria strain-specific infections. It has to be pointed out that our assay is not IBV lineage specific, since IBVs of different lineages show very high homology for the viral internal proteins and relatively high homology for the envelope glycoproteins. Our results indicate that lineage-specific antigens enable higher sensitivity in the detection of changes in the antibody levels.
In the present study, we have developed a multiplexed serological microarray assay and demonstrated its excellent performance for the screening of a large number of serum specimens collected from young children for the presence of IgG antibodies against several viruses or viral antigens. The data presented show that young children are highly susceptible to respiratory infections and the frequency of reinfections is relatively high. With the developed microarray method we can obtain quantitative data and estimate not only sample seropositivity but also IgG antibody levels and changes between serial serum specimens and possible reinfection rates. The overall performance and technical features of the assay showed that the platform supports viral cycles]) to disperse aggregates. Then 50 l/well of anti-hIgG-coated UCNPs was added into the wells and incubated for 40 min at room temperature with slow shaking. After four washes, the plates were dried for 2 h and the wells were imaged with an anti-Stokes photoluminescence imager constructed for multianalyte detection (19) . The emission of UCNPs was detected through a 650-nm short-pass filter (Chroma Technology, Rockingham, VT) with a cooled charge-coupled-device (CCD) camera (Andor Clara with Sony ICX285 CCD; Andor Technology, South Windsor, CT) using 2ϫ binning, a 2.2-s exposure time per well, and laser excitation at 976 Ϯ 2 nm with 7 W of optical power. Image analysis program. Image analysis was performed with ImageJ software version 1.43n. The computer program was written in Visual Basic language to aid in microarray analysis. Although existing software solutions were available (29, 30) , a more flexible and alterable analysis platform was desired. The program was designed to semiautomatically address, segment, and quantitate the spots from a batch of microarray images that had the same array specifications and spot radii. The array specifications, including row and column counts, were used as input information to estimate the position, rotation, and scale of the array grid with the Radon transform (31, 32) . Spots were segmented from the estimated positions using a fixed-size circular area where the radius was the average of all the detected spot boundary radii in the batch of microarray images. The final positioning and radius adjustments were done manually in the program. The computer program read unsigned 16-bit grayscale raw images where the intensity value of a single pixel ranged from 0 to 65,535. An average pixel intensity, standard deviation, and minimum and maximum intensities were automatically calculated from each circular spot area, and no automatic background subtraction was calculated or directly applied.
Data analysis. The antibody concentration, expressed as EIA and MAIA units, was calculated from the linear plot of the calibrators using Microsoft Excel version 2010 (Microsoft Corp., USA). Data depicted on box plots were analyzed and graphed using Origin version 2016 (OriginLab, USA). All other statistical analyses were performed using IBM SPSS Statistics version 22 software (IBM Corp., USA). Differences between groups were analyzed by independent-sample t test, where significance was set at a P value of Ͻ0.05. Agreement between EIA and MAIA was analyzed using ROC analysis, Cohen's statistic, and Pearson correlation.
